Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Moneyclipon Feb 17, 2007 7:15pm
216 Views
Post# 12257496

RE: DD help

RE: DD helpSSS patent technology was acquired from Dr. Samuel Wiess and his research team at the University of Calgary, here are a few links with info on Dr. Weiss and his research. https://www.abheritage.ca/abinvents/inventors/samuel_weiss_biography.htm https://en.wikipedia.org/wiki/Samuel_Weiss https://www.cell.ucalgary.ca/s_weiss.html https://www.ucalgary.ca/gdrg/weiss.htm https://www.ucalgary.ca/community/research/samuel_weiss
Bullboard Posts